Distortion of maternal-fetal angiotensin II type 1 receptor allele transmission in pre-eclampsia

L Morgan, S Crawshaw, P N Baker, J F Y Brookfield, F Broughton Pipkin, N Kalsheker

Abstract

Objective—To investigate the fetal angiotensin II type 1 receptor genotype in pre-eclampsia.

Design—Case-control study.

Population—Forty-one maternal-fetal pairs from pre-eclamptic pregnancies and 80 maternal-fetal pairs from normotensive pregnancies.

Methods—Maternal and fetal DNA was genotyped at three diallelic polymorphisms, at nucleotides 573, 1062, and 1166, in the coding exon of the angiotensin II type 1 receptor gene, and at a dinucleotide repeat polymorphism in its 3’ flanking region.

Results—Allele and genotype frequencies at the four polymorphic regions investigated did not differ between pre-eclamptic and normotensive groups, in either fetal or maternal samples. Mothers heterozygous for the dinucleotide repeat allele designated A4 transmitted this allele to the fetus in 15 of 18 informative pre-eclamptic pregnancies and in eight of 26 normotensive pregnancies. This was greater than the expected probability in pre-eclamptic pregnancies (p=0.04) and less than expected in normotensive pregnancies (p=0.005). The 573T variant, which is in partial linkage disequilibrium with the A4 allele, showed a similar distortion of maternal-fetal transmission. Conclusion—Angiotensin II type 1 receptor gene expression in the fetus may contribute to the aetiology of pre-eclampsia. It is unclear whether susceptibility is conferred by the fetal genotype acting alone, or by allele sharing by mother and fetus. Possible mechanisms for the effect of the angiotensin II type 1 receptor gene are suggested by the association of the 573T variant with low levels of surface receptor expression on platelets. If receptor expression is similarly genetically determined in the placenta, responsiveness to angiotensin II may be affected, with the potential to influence placentation or placental prostaglandin secretion.

(J Med Genet 1998;35:632-636)

Keywords: pre-eclampsia; angiotensin II type 1 receptor

It is widely recognised that pre-eclampsia, the severe proteinuric form of pregnancy induced hypertension, has an inherited component.1 The model of inheritance has not been defined; in particular, the contribution of the fetal genotype is unclear. Epidemiological studies are consistent with dominant maternal inheritance with partial penetrance2 and fetal factors may influence penetrance. Indeed, some epidemiological evidence supports a model of gene sharing between mother and fetus in the aetiology of pre-eclampsia.3

Although pre-eclampsia presents clinically in the second half of pregnancy, impaired trophoblastic invasion of the myometrial segment of maternal spiral arteries during early pregnancy is a characteristic feature.4 The resulting altered placental haemodynamics and placent al ischaemia may be factors in the aetiology of pre-eclampsia.5 The placenta is unusual among vascular beds in having no autonomic nerve supply; vascular resistance on the fetal side of the circulation is determined by humoral factors, including angiotensin II (AII), the vasoactive peptide formed by sequential cleavage of angiotensinogen by renin and angiotensin converting enzyme. Angiotensin II receptors with the pharmacological characteristics of type 1 (AT1) receptors have been found in resistance vessels in term placenta6 and are presumably encoded by the fetal gene. They are present at decreased density in term placentae from pre-eclamptic pregnancies and from pregnancies complicated by intrauterine growth retardation.7 One possible explanation is that hypo-oxygenation stimulates the fetal renin-angiotensin system8 and the resulting rise in fetal plasma angiotensin II concentrations downregulates the placental AT1 receptors.

Angiotensin II stimulates placental prostacyclin secretion.9 The receptor subtype responsible has yet to be identified in the placenta. However, at least a proportion of the stimulatory effect of angiotensin II on prostaglandin synthesis in porcine vascular smooth muscle was mediated via AT1 receptors.10 Impaired secretion of vasodilatory eicosanoids antedates the onset of clinical hypertension in pre-eclampsia11 and contributes to the increased maternal pressor responsiveness to infused angiotensin II in this condition.12 It is possible that placental AT1 receptor expression influences both placental haemodynamics and maternal systemic haemodynamics through its effects on placental prostaglandin secretion.

In an earlier study comparing women with pre-eclampsia with normotensive pregnant women, we found no significant difference between the two groups of women in the frequency of three diallelic polymorphisms in the coding exon of the AT1 receptor gene, at nucleotides 573, 1062 and 1166, or in the allele distribution of a dinucleotide repeat polymorphism in its 3’ flanking region.13 In this preliminary study, fetal genotyping from these
pregnancies has been performed to test the hypothesis that the fetal AT1 receptor genotype is associated with pre-eclampsia. Results were examined both for allele association and for evidence of distortion of allele transmission from mother to fetus in pre-eclamptic pregnancies.

Methods

Subjects and Samples
Eighty normotensive pregnant women (71 primigravid, nine multigravid) and 41 women with pre-eclampsia (33 primigravid, eight multigravid) were recruited during the second half of pregnancy. The mean (SD) age of normotensive women was 27.8 (4.0) and of women with pre-eclampsia was 28.3 (5.8). All subjects were white. Pre-eclampsia was defined as a diastolic blood pressure exceeding 90 mm Hg and a systolic blood pressure exceeding 140 mm Hg in a previously normotensive woman, which returned to normal within three months of delivery, and was associated with proteinuria in excess of 300 mg/l in a 24 hour collection or two pluses on dipstick testing of a random sample. Maternal genotyping was performed on DNA extracted from peripheral venous blood. Fetal DNA was extracted from umbilical venous blood or umbilical cord samples obtained at delivery if possible, or on filter paper blood spots (Guthrie spots) retrieved from the Trent Regional Neonatal Screening Unit archive. Eighteen (44%) babies born of pre-eclamptic pregnancies and 43 (54%) born of normotensive pregnancies were male; this difference was not statistically significant (p>0.05). All deliveries were singleton live births.

All mothers gave informed consent, on behalf of themselves and their babies, for participation in the study, which was approved by the hospital Ethics Committee.

Genotyping at Diabetic Polymorphisms
A 1 kb fragment of the coding exon of the AT1 receptor gene, including part of the coding region and approximately 400 bases of the 3' untranslated region, was amplified by the polymerase chain reaction (PCR). Amplification reactions were carried out in a total volume of 25 μl, using 100 to 200 ng genomic DNA or 1 mm² filter paper blood spot, 200 μmol/l dNTPs, 25 pmol of each primer, 50 mmol/l KCl, 10 mmol/l Tris HCl (pH 9.0), 0.1% Triton X-100, 1.5 mmol/l MgCl₂, and 1 U Taq polymerase. Primer sequences are shown in Table 1. Samples were overlaid with 20 μl of mineral oil, loaded onto a thermal cycler, and denatured at 96°C for five minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for one minute, and 72°C for one minute, with a final 10 minute extension stage at 72°C. DNA free controls were run with each batch to detect DNA contamination of reagent solutions.

Subjects were genotyped at three diuretic polymorphisms (573C to T, 1062A to G, and 1166A to C) by competitive allele specific oligonucleotide (ASO) hybridisation. A total of 2 μl (approximately 50 ng) of each PCR product was denatured in 125 μl of 0.2 N NaOH/2 × SSC and spotted onto duplicate nylon membranes (Hybond N*, Amersham). Oligonucleotides were synthesised corresponding to wild type and mutant sequences at each site (Table 2). Each membrane was prehybridised for one hour at 52°C in 10 ml 5 × SSPE/1% SDS containing 30 pmol of unlabelled oligonucleotide corresponding to wild type or mutant sequence, then hybridised for one hour at 52°C in 10 ml 5 × SSPE/1% SDS containing 3 pmol of the alternative 32P end labelled ASO. Membranes were washed in 2 × SSPE/0.1% SDS for two 30 minute periods at room temperature, then for 15 minutes in 5 × SSPE/0.1% SDS at 52°C, and autoradiographed at −70°C for 16 hours. Genotyping was confirmed by sequencing at least one sample of each genotype detected.

Dinucleotide Repeat Polymorphism
Subjects were genotyped at the dinucleotide repeat polymorphism (CA) in the 3' flanking region of the AT1 receptor gene by electrophoresis of radiolabelled PCR products on denaturing polyacrylamide gels using the primers shown in Table 1. Amplification reactions were carried out in a total volume of 20 μl, using 100 to 200 ng genomic DNA or 1 mm² filter paper blood spot, 200 μmol/l dNTPs, 20 pmol of each unlabelled primer, 0.2 pmol of one primer end labelled with 32P-ATP, 50 mmol/l KCl, 10 mmol/l Tris HCl (pH 9.0), 0.1% Triton X-100, 1.5 mmol/l MgCl₂, and 1 U Taq polymerase. Samples were denatured at 96°C for five minutes, followed by 35 cycles of 30 seconds at 94°C, one minute at 50°C, and one minute at 72°C, with a final 10 minute extension stage at 72°C. DNA free controls were run with each batch to detect DNA contamination of reagent solutions. PCR products were heat denatured at 96°C in 95% formamide, and resolved by electrophoresis on 6% polyacrylamide/7 mol/l urea denaturing gels run at 45 W for two hours. The gels were dried and autoradiographed. The alleles were numbered as in the original description of this polymorphism, whereby the most common allele is designated A4. A sample from a single subject of genotype A4/A7 was included on every gel to ensure consistency of allele assignment.

Table 1: Oligonucleotide primers used for AT1 receptor gene amplification

<table>
<thead>
<tr>
<th>Primer</th>
<th>Nucleotides</th>
<th>Strand</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATR1</td>
<td>422 to 443</td>
<td>Sense</td>
<td>5' ATGGCCTTGACGCAAGTGCACCT</td>
</tr>
<tr>
<td>ATR2</td>
<td>1458 to 1436</td>
<td>Antisense</td>
<td>5' CCGTTGCTCCTCTCCGATTTA</td>
</tr>
<tr>
<td>ATCA1</td>
<td>3' FR</td>
<td>GT</td>
<td>5' AGGAAAGATTTCCAAGGGAACA</td>
</tr>
<tr>
<td>ATCA2</td>
<td>3' FR</td>
<td>CA</td>
<td>5' GTATTCCATGTGAAACAGCTCCA</td>
</tr>
</tbody>
</table>

Table 2: Allele specific oligonucleotides used in competitive hybridisation assays

<table>
<thead>
<tr>
<th>Polymorphic site</th>
<th>Allele specific oligonucleotides</th>
</tr>
</thead>
<tbody>
<tr>
<td>573 C to T</td>
<td>5' GAAACCCTT or TGGGATAG</td>
</tr>
<tr>
<td>1062 A to G</td>
<td>5' CCCTGACCA or GTTGGTTTGAAG</td>
</tr>
<tr>
<td>1166 A to C</td>
<td>5' AATGACCA or CTGGATAG</td>
</tr>
</tbody>
</table>
Table 3  Maternal and fetal allele frequencies for three diallelic polymorphisms in the AT, receptor gene for 80 normotensive (NT) and 41 pre-eclamptic (PE) pregnancies. The mutant allele frequency is shown in each case

<table>
<thead>
<tr>
<th>Location</th>
<th>Polymorphism</th>
<th>Maternal</th>
<th>Fetal</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coding region</td>
<td>C to T</td>
<td>0.47 0.43</td>
<td>0.42 0.52</td>
<td>-0.09 to 0.29</td>
</tr>
<tr>
<td>Coding region</td>
<td>A to G</td>
<td>0.11 0.09</td>
<td>0.08 0.16</td>
<td>-0.11 to 0.07</td>
</tr>
<tr>
<td>Coding region</td>
<td>A to C</td>
<td>0.27 0.29</td>
<td>0.30 0.25</td>
<td>-0.22 to 0.12</td>
</tr>
</tbody>
</table>

\[
\frac{\text{[PE]} - \text{[NT]}}{\text{[NT]}} = 95\% \\
\]

Table 4  Fetal and maternal AT, receptor gene dinucleotide repeat allele frequencies from 80 normotensive and 41 pre-eclamptic pregnancies

<table>
<thead>
<tr>
<th>Allele</th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>A4</th>
<th>A5</th>
<th>A6</th>
<th>A7</th>
<th>A8</th>
<th>A9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normotensive</td>
<td>0.03</td>
<td>0.14</td>
<td>0.21</td>
<td>0.41</td>
<td>0.04</td>
<td>0.06</td>
<td>0.06</td>
<td>0.06</td>
<td>0.05</td>
</tr>
<tr>
<td>Pre-eclamptic</td>
<td>0.02</td>
<td>0.10</td>
<td>0.16</td>
<td>0.51</td>
<td>0.05</td>
<td>0.04</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normotensive</td>
<td>0.03</td>
<td>0.13</td>
<td>0.16</td>
<td>0.46</td>
<td>0.06</td>
<td>0.07</td>
<td>0.06</td>
<td>0.03</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Pre-eclamptic</td>
<td>0.02</td>
<td>0.15</td>
<td>0.11</td>
<td>0.40</td>
<td>0.11</td>
<td>0.07</td>
<td>0.12</td>
<td></td>
<td>0.01</td>
</tr>
</tbody>
</table>

STATISTICAL METHODS

Allele and genotype frequencies from pre-eclamptic and normotensive pregnancies were compared using the chi squared test with Yates's correction or Fisher's exact test where appropriate. Distortion of dinucleotide repeat allele transmission from heterozygous mothers was assessed by testing of informative pregnancies, that is, those in which the mother was heterozygous and the fetal genotype differed from the maternal genotype, in a two step analysis. For each dinucleotide repeat allele, the number of alleles transmitted in informative pre-eclamptic and normotensive pregnancies was compared using a two tailed Fisher's exact test. Significance levels were adjusted for testing of multiple alleles using the Bonferroni correction. For any allele for which this initial test showed significant distortion of transmission, the results were further examined in pre-eclamptic and normotensive pregnancies individually. For each allele, Ai, the probability of Ai being transmitted to the fetus conditional on the pregnancy being informative was calculated as follows: estimates of allele frequencies, Pi, were obtained by pooling results of maternal genotyping from normotensive and pre-eclamptic pregnancies. Consider a mother who is heterozygous for a specific Ai allele, and of genotype Ai/Aj, where Aj is any allele other than Ai, with frequency Pj. The probability that she has the specific allele Aj, and is thus Ai/Aj, is Pj/(1-Pj). If such a mother passes on the Ai allele, with probability 0.5, the probability that the pregnancy is informative (that is, the fetus has a paternal allele other than Aj) is 1-Pj. The total probability that a heterozygous female passes on Ai and is informative is thus

\[
0.5 \left( \sum_{j} P_{j}(1-P_{j}) \right) = a \\
(1 - P_{j})
\]

If the mother passes on the Aj allele, with probability 0.5, the probability that the pregnancy is informative (that is, the fetus has a paternal allele other than Ai) is 1-Pi for all j. Thus the probability that an Ai/Aj heterozygote passes on Aj and is informative is 0.5(1-Pj)=b.

The total probability that a maternal-fetal pair is informative is thus ab, and the probability of a mother who is heterozygous for Ai transmitting Ai, conditional on the pregnancy being informative, is a/(a+b). The observed number of alleles transmitted was compared with the expected transmission, based on the estimated conditional probability, using a binomial exact test.

Results

There were no significant differences between normotensive and pre-eclamptic groups in the allele or genotype frequencies of diallelic polymorphisms, or in the distribution of dinucleotide repeat alleles, in either fetal or maternal samples (tables 3 and 4, p>0.05). The results of maternal genotyping have been reported previously1; they are reproduced here for ease of reference.

The highly polymorphic nature of the dinucleotide repeat polymorphism permitted tracking of allele transmission in a proportion of maternal-fetal pairs; 51% normotensive (n=41) and 66% pre-eclamptic (n=27) pregnancies were informative. Results are shown in table 5. One allele, designated A4, showed significant differences in allele transmission when normotensive pregnancies were compared with pre-eclamptic pregnancies (nominal significance p<0.001, two tailed Fisher's exact test; corrected for testing of multiple alleles p<0.01). The estimated probability of transmission of the A4 allele, conditional on the pregnancy being informative, was 0.615. In the pre-eclamptic group, transmission of the A4

Table 5  Number (proportion) of AT, receptor gene dinucleotide repeat alleles transmitted from mother to fetus in 41 informative normotensive pregnancies and 27 pre-eclamptic pregnancies

<table>
<thead>
<tr>
<th>Allele</th>
<th>Homozygous</th>
<th>Heterozygous</th>
<th>Informative pregnancies</th>
<th>Maternal-fetal transmission</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>0</td>
<td>5</td>
<td>4</td>
<td>3 (0.75)</td>
</tr>
<tr>
<td>A2</td>
<td>2</td>
<td>17</td>
<td>11</td>
<td>5 (0.45)</td>
</tr>
<tr>
<td>A3</td>
<td>3</td>
<td>19</td>
<td>14</td>
<td>11 (0.79)</td>
</tr>
<tr>
<td>A4</td>
<td>17</td>
<td>39</td>
<td>26</td>
<td>8 (0.31)</td>
</tr>
<tr>
<td>A5</td>
<td>0</td>
<td>10</td>
<td>9</td>
<td>3 (0.33)</td>
</tr>
<tr>
<td>A6</td>
<td>1</td>
<td>9</td>
<td>6</td>
<td>3 (0.50)</td>
</tr>
<tr>
<td>A7</td>
<td>0</td>
<td>10</td>
<td>8</td>
<td>5 (0.63)</td>
</tr>
<tr>
<td>A8</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>3 (1.00)</td>
</tr>
<tr>
<td>A9</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*Significant excess of A4 alleles transmitted from mother to fetus in pre-eclamptic compared with normotensive pregnancies; p<0.001 (two tailed Fisher's exact test); p<0.01, corrected for testing of multiple alleles.
Fetal AT, receptor gene in pre-eclampsia

635

allele from mother to fetus exceeded the expected probability (p=0.04, binomial exact test), while in the normotensive group, the A4 allele was transmitted from mother to fetus less frequently than expected (p<0.005).

Of the di allelic polymorphisms, only that at nucleotide 573 provided a sufficient number of heterozygous pregnancies for meaningful statistical analysis of allele transmission (21 pre-eclamptic, 40 normotensive). The probability of a heterozygous mother transmitting the variant 573T allele conditional on the pregnancy being informative was 0.454. The 573T allele was transmitted from mother to fetus in nine of 13 informative pre-eclamptic pregnancies, marginally more frequently than expected (p=0.07), and in five of 23 informative normotensive pregnancies, significantly less frequently than expected (p=0.02). These observations complement those relating to transmission of the dinucleotide repeat alleles, as the A4 allele and the 573T allele are in partial positive linkage disequilibrium.13

Discussion

This study provides preliminary evidence that in pre-eclampsia there is distortion of transmission from mother to fetus of an AT, receptor allele. The dinucleotide repeat allele designated A4 is transmitted in excess in pre-eclamptic pregnancies. A similar trend was observed in the smaller number of pregnancies informative for transmission of the 573T variant. As a corollary of this observation, these alleles are transmitted less frequently than expected in normotensive pregnancies. Dinucleotide repeats are widely distributed in the genome, and may be involved in crossover of genetic material during meiosis.16 There is no evidence that variation in the number of repeats has functional effects, and their main value to molecular geneticists is as highly polymorphic allelic markers. The C to T mutation at nucleotide 573 similarly has no known functional effects; although it lies within the coding region of the gene, it does not alter the encoded amino acid residue.14 Both the A4 allele and the 573T allele may therefore be acting as markers for a linked mutation at a functional site. In our earlier study of the maternal AT, receptor genotypes in this group of subjects, normotensive pregnant women possessing either one or two copies of the 573T variant had lower levels of AT, surface receptors, measured as platelet AII binding, than women homozygous for the 573C allele.17 This suggests that the polymorphism at nucleotide 573 is in linkage disequilibrium with a variant which affects AT, receptor expression in platelets. Whether vascular and placental AT, receptor expression are similarly lower in association with the 573T variant is at present unknown.

Altered AT, receptor expression at the maternal-fetal interface could potentially influence placental haemodynamics. Vascular response elements modulating maternal blood flow to the placenta lie in the uterine, radial, and basal arteries.18 The spiral arteries normally lose their pressor responsiveness during trophoblast invasion, although they retain the ability to constrict in pre-eclampsia, where invasion of their myometrial segment during placentation is inadequate. Vascular elements on the fetal side of the placenta, vascular response elements lie entirely on the fetal side of the circulation. The major resistance vessels are the previllous arterioles. The effects of angiotensin II in the control of placental circulation are complex. Angiotensin II causes constriction of the resistance vessels19 while stimulating placental secretion of vasodilatory prostaglandins.20 Reduced placental AT, receptor expression may be a primary factor in impaired placental prostaglandin secretion in pre-eclampsia, resulting in inadequate placental vasodilation and placental ischaemia, followed in due course by the appearance of the pre-eclamptic phenotype in the mother.

More speculative are the possible effects of reduced AT, receptor expression on trophoblast invasion and placentation. The factors determining successful implantation and placentation are incompletely understood. Angiotensin II has been shown to induce neovascularisation when implanted into rabbit cornea20 and has a dose dependent angiogenic effect when applied to chick chorioallantoic membrane.21 While not conclusive in themselves, these observations indicate that angiotensin II does at least merit serious consideration as a factor required for successful placentation. Low trophoblast responsiveness to angiotensin II, resulting from low AT, receptor expression, could then lead to impaired placentation and pre-eclampsia.

Reduced transmission of the A4 allele in normotensive pregnancies is difficult to explain. Statistically, this is more significant than the increased A4 allele transmission in pre-eclamptic pregnancies, although this may be partly because of the larger number of informative pregnancies in the normotensive group (n=26) compared with the pre-eclamptic group (n=18). It is worth noting that the significance values are highly sensitive to the calculated probability of allele transmission conditional on the pregnancy being informative, which is in turn dependent on estimated allele frequencies. As the value of the conditional probability of allele transmission tends towards the unconditional probability of 0.5, the observed deficit of A4 allele transmission in normotensive pregnancies becomes less statistically significant, while the excessive allele transmission in the pre-eclamptic group becomes more significant.

In conclusion, we present preliminary evidence that in a subgroup of pregnancies there is distortion of transmission of an AT, receptor allele variant, which appears to be associated with pre-eclampsia. These observations require independent confirmation. Increased maternal-fetal transmission of an AT, receptor allele in pre-eclampsia is consistent with a purely fetal genetic contribution; alternatively, susceptibility to pre-eclampsia may require both mother and fetus to express the same AT, receptor allele. Possible explanatory mechanisms are suggested by the observation that this variant is associated with relatively low receptor expression on the platelets of normotensive
pregnant women. If the levels of receptor expression in the trophoblast and placenta are similarly genetically determined, possession of this allele by the fetus may result in relative refractoriness to the effects of angiotensin II, affecting placentation, placental prostacyclin secretion, and placental haemodynamics.

We wish to thank Dr R Pollitt and Dr D Curtis for providing access to samples stored in the Trent Regional Neonatal Screening Unit archive. Financial assistance from the Medical Research Council, Trent Regional Health Authority, and Nottingham Hospital Trustees is gratefully acknowledged.

5 Roberts JM, Redman CGW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-54.
Distortion of maternal-fetal angiotensin II type 1 receptor allele transmission in pre-eclampsia.

L Morgan, S Crawshaw, P N Baker, J F Brookfield, F Broughton Pipkin and N Kalsheker

doi: 10.1136/jmg.35.8.632

Updated information and services can be found at:
http://jmg.bmj.com/content/35/8/632

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/